H.C Wainwright Asserts Buy Stance as ImmunityBio, Inc. (IBRX) Achieves Positive Results on Bladder Cancer Treatment

AI Summary

Author presents a long-term bullish thesis on ImmunityBio (IBRX), citing ANKTIVA's commercial stage, bladder cancer data, and 2026 catalysts while noting reliance, Phase 3 timing, and dilution risks.

IBRX — LONG The author views IBRX as a long-term hold of at least 2–3 years rather than a swing trade, citing ImmunityBio's commercial-stage ANKTIVA bladder cancer therapy and positive results. Near-term catalysts include EU/UK approval decisions for ANKTIVA plus BCG in non-muscle invasive bladder cancer, continued U.S. commercial growth with reimbursement in place, Phase 3 NSCLC enrollment completion expected in early 2026, and possible ASCO/AACR data updates. Stated risks are heavy reliance on ANKTIVA, major U.S. lung cancer approval depending on Phase 3 data not expected until 2027, biotech/regulatory volatility, and potential dilution given the company's debt.

But I do see this as a long term hold minimum 2-3 years. not swing trade

Score 4

Comments 4

▶ Full Post Text

Ideas

u/HopefulChain7006 Reddit r/pennystocks

Long-term hold; ANKTIVA catalysts, Phase 3 NSCLC, dilution risk

The author views IBRX as a long-term hold of at least 2–3 years rather than a swing trade, citing ImmunityBio's commercial-stage ANKTIVA bladder cancer therapy and positive results. Near-term catalysts include EU/UK approval decisions for ANKTIVA plus BCG in non-muscle invasive bladder cancer, continued U.S. commercial growth with reimbursement in place, Phase 3 NSCLC enrollment completion expected in early 2026, and possible ASCO/AACR data updates. Stated risks are heavy reliance on ANKTIVA, major U.S. lung cancer approval depending on Phase 3 data not expected until 2027, biotech/regulatory volatility, and potential dilution given the company's debt.

▶ Full Post Text

Ideas

More from Reddit — r/pennystocks